Skip to content

H.R. 4053 · 118th Congress (2023–2025)

Studying Suboxone Act

This bill requires the Department of Health and Human Services (HHS) and the Drug Enforcement Administration (DEA) to reevaluate the scheduling of buprenorphine-naloxone combination products (e.g., suboxone) under the Controlled Substances Act. These products are used to treat opioid addictions and are currently schedule III controlled substances. (A schedule III controlled substance is a drug, substance, or chemical that has less potential for abuse than a schedule I or II substance; that has a currently accepted medical use; and that has low or moderate risk of dependence if abused.)

Specifically, the bill requires HHS to review scientific and medical evaluations relating to these products and update its scheduling recommendations accordingly. The DEA must review the recommendations of HHS and make appropriate scheduling changes.

!--tinycomments|2.1|data:application/json;base64,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-->
Show official title

To provide for the review of the scheduling under the Controlled Substances Act of buprenorphine-naloxone combination products, and for other purposes.

Expired in House committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to Health

This bill’s path

This is H.R. 4053’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. Ann M. Kuster (D-NH-2)
Cosponsors
3 cosponsors

1 original · 2 later

  1. Rep. Earl L. "Buddy" Carter (R-GA-1)· Original · Jun 13, 2023
  2. Rep. Paul Tonko (D-NY-20)· Later · Jun 20, 2023
  3. Rep. Marcus J. Molinaro (R-NY-19)· Later · Jan 3, 2024
Policy area
Health
Subjects
  • Drug trafficking and controlled substances
  • Government studies and investigations

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 2 committee actions · Jun 13, 2023 – Jun 16, 2023
    1. Referred to committee

      Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
  3. Expired

    Introduced → Referred to House Health → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred Jun 13, 2023
  2. HouseHealthReferred Jun 16, 2023
    1. Jun 21, 2023 · Meeting

  3. HouseJudiciaryReferred Jun 13, 2023

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (2)
  1. Studying Suboxone Act

    Display title, Short title · Introduced in House

  2. To provide for the review of the scheduling under the Controlled Substances Act of buprenorphine-naloxone combination products, and for other purposes.

    Official title · Introduced in House